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SARS-CoV-2 utilizes the IMPa/b1 heterodimer to enter host cell nuclei after gaining cellular access
through the ACE2 receptor. Ivermectin has shown antiviral activity by inhibiting the formation of the
importin-a (IMPa) and IMPb1 subunits as well as dissociating the IMPa/b1 heterodimer and has in vitro
efficacy against SARS-CoV-2. Plasma and lung ivermectin concentrations vs. time profiles in cattle were
used to determine the apparent plasma to lung tissue partition coefficient of ivermectin. This coefficient,
together with a simulated geometric mean plasma profile of ivermectin from a published population
pharmacokinetic model, was utilized to develop a minimal physiologically-based pharmacokinetic
(mPBPK) model. The mPBPK model accurately described the simulated ivermectin plasma concentration
profile in humans. The mPBPK model was also used to simulate human lung exposure to ivermectin after
12, 30, and 120 mg oral doses. The simulated ivermectin lung exposures reached a maximum concen-
tration of 772 ng/mL, far less than the estimated 1750 ng/mL IC50 reported for ivermectin against SARS-
CoV-2 in vitro. Further studies of ivermectin either reformulated for inhaled delivery or in combination
with other antivirals with differing mechanisms of action is needed to assess its therapeutic potential.
© 2020 Published by Elsevier Inc. on behalf of the American Pharmacists Association.Introduction
The novel SARS-CoV-2 coronavirus causes COVID-19 and has
caused a global pandemic resulting in over twenty-four million
infections and eight hundred thousand deaths at the time of
writing. Healthcare providers and researchers are currently
repurposing approved drugs in an attempt to treat COVID-19gues was partially supported
tro (Argentina), and Agencia
08-00000-00817) Argentina.
an School of Pharmacy, Uni-
lf of the American Pharmacists Aspatients as urgent efforts to develop effective vaccines and treat-
ments continue.
SARS-CoV-2 causes infection through entering host cells by
binding to angiotensin-converting enzyme 2 (ACE2) receptors,
which are present in many tissues but predominantly human
alveolar epithelial cells.1,2 Ivermectin is an approved human and
animal anthelmintic which has also shown antiviral properties.
Ivermectin inhibits the formation of the importin-a (IMPa) and
IMPb1 subunits as well as causes the dissociation of the formed
IMPa/b1 heterodimer.3e7 The IMPa/b1 heterodimer is thought to be
used by the SARS-CoV-2 nucleoprotein to infiltrate the nucleus,
thereby delaying cellular proliferation and establishing an optimal
environment inside the host cell for virus assembly and repli-
cation.8e10 Previous studies have shown in vitro activity of iver-
mectin against other RNA viruses such as the Zika, dengue-related
West Nile, dengue, human immunodeficiency, and influenzasociation.
Table 1
Model Predicted Pharmacokinetic Parameter Estimates and Resulting Precision.
Parameter Description Estimate (CV%) Units
Ka Absorption rate 0.14 (2.52) Hr1
Vpa Plasma volume 315 L
CLp/F Plasma clearance 10.85 (3.78) L/hr
VLa Lung volume 1.314 L
Kp, lung/Fa Lung partition coefficient 2.68 e
Qcoa Cardiac output 28215 L/hr
VOthera Remaining volume 65.7 L
Kp, other/F Tissue partition coefficient 17.32 (5.6) e
Fraction Fraction of cardiac output 0.08 (1.18) e
Ktr Transit rate 0.36 (3.09) hr1
a Parameter not estimated.
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cell nuclei.3,7 More recently, ivermectin has demonstrated in vitro
activity against SARS-CoV-2 with a reported IC50 value of 1750 ng/
mL (2 mM).11
Understanding the pharmacokinetics (PK) and penetration of
ivermectin to the site of infection and intended action, the lung in
the case of SARS-CoV-2, is an important step in transferring in vitro
knowledge to potential in vivo utilization. Therefore, the objective
of this study was to develop a minimal physiologically-based
pharmacokinetic (mPBPK) model to simulate human lung expo-
sure of ivermectin after oral administration.Materials and Methods
Ivermectin Pharmacokinetic Data
Ivermectin lung and plasma concentrations in Holstein calves
were obtained from studies performed by Lifschitz and colleagues
(including unpublished data found in Table S1 of the supplemen-
tary material).12 Calves were treated with ivermectin by subcu-
taneous injection at 0.2 mg/kg using a commercially available
formulation for cattle. Lung homogenates from the left lobus cra-
nialis and plasma samples obtained between 1 and 48 days post-Fig. 1. Schematic of the developed mPBPK model for ivermectin following administration o
identical to the plasma compartment on the right. The mPBPK model comprises two tissue c
all of the cardiac output while the other compartment describing the rest of the body re
described by a transit compartment. Symbols are defined in Table 1.treatment were analyzed by high-performance liquid chromatog-
raphy. Animal procedures were performed according to the Animal
Welfare Policy of the Faculty of Veterinary Medicine, Universidad
Nacional del Centro de la Provincia de Buenos Aires (UNCPBA),
Tandil, Argentina.
Parameter estimates from a phase 1 study assessing the PK of
ivermectin in 18 subjects receiving a 0.2 mg/kg dose orally were
utilized to simulate a geometric mean plasma concentration profile
in humans without residual unexplained variability (RUV) or
interindividual variability using Phoenix® WinNonlin (Version 8.2,
Certara USA, Inc.; Princeton, NJ).13 The average dose administered
in the study, 15 mg, was used for the simulation.Parameters
Physiologic parameters for cardiac output, lung, and plasma
volume were based on population averages.14,15 The species-
independent apparent lung partition coefficient, Kp, lung/F, was
determined by dividing ivermectin lung area under the curve (AUC)
by the plasma AUC obtained from the cattle study.12 The absorption
rate (Ka), apparent plasma clearance (CLp/F), fraction of cardiac
output to other tissues (Fraction), apparent partition coefficient (Kp,
other/F), and transit rate (Ktr) for humans were estimated using the
matrix exponential solver in Phoenix® WinNonlin (Version 8.2,
Certara USA, Inc.). A multiplicative error model was evaluated to
describe the RUV of the simulated human plasma data during the
mPBPK model development.Human Lung Exposure Simulation
Human lung and plasma exposure simulations were performed
with the final model parameters reported in Table 1 as well as an
assumed 20% RUV in R (version 4.0.2) using the mrgsolve package
(version 0.10.4) by simulating 1000 patients at observation time
intervals of 0.1 h. Therapeutic and supra-therapeutic single doses of
ivermectin (12, 30, and 120 mg) were evaluated. The 12 mg dose
was simulated to represent the typical single dose of ivermectin
administered to humans while the supratherapeutic 30 and 120mgf an oral dose in humans (Dose). The plasma compartment (dashed line) on the left is
ompartments (Lung and Other) and a plasma compartment (Plasma). The lung receives
ceives a fraction of the cardiac output. The delay following oral dosing in humans is
dPla
d
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be safe with minimal toxicities and exhibiting linear pharmacoki-
netics.16 A 95% confidence interval of the simulated human plasma




The resulting mPBPKmodel shown in Fig. 1 adequately captured
the simulated geometric mean plasma PK profile in humans (Fig. 2).
Parameters
Model estimates and precision (CV%) for Ka, CLp/F, Fraction, Kp,
other/F, and Ktr are shown in Table 1. Parameter precision around
data-informed parameters such as Ka and CLp/F were below 5%. The
Kp,other/F estimate of 17.3 conditioned on bioavailability, could be
explained by ivermectin's large volume of distribution (estimated
to be ~1077 L) as well as the potential poor bioavailability from oral
administration of this highly lipophilic drug.13
Model Equations
The following system of ordinary differential equations de-
scribes the mPBPK model schematic shown in Fig. 1:
Ivermectin disposition in humans is described by an mPBPK
model containing compartments for absorption, plasma, lung, and
the rest of the body (Other). The transit compartment (a0) accounts
for the delay in transit through the gastrointestinal tract, and the







¼  Ka*Doseþ Ktr*a0
where Ktr is the transit rate constant, a0 is the amount of iver-
mectin in the transit compartment at a given time, Ka is the first-
order absorption rate constant, and Dose is the orally adminis-
tered dose of ivermectin.








































* Qco * Fraction

Other represent the amount of ivermectin and VL, Vp, and VOther
represent the physiological volumes of the lung, plasma, and the
rest of the body, respectively. Qco is the cardiac output, and Fraction
is the fraction of cardiac output that perfuses the rest of the body e
the Other compartment. Kp,lung/F is the cattle-informed apparent
tissue partition coefficient, Kp,other/F is the apparent tissue partition
coefficient for the rest of the body e the Other compartment e and
CLp/F is the apparent clearance of ivermectin from the plasma
where F represents bioavailability.





































Human Lung Exposure Simulation
Human lung exposure simulations following oral administration
of 120 mg ivermectin are shown in Fig. 3A while the plasma profile
is shown in Fig. 3B. Profiles for human plasma and lung exposure
simulations resulting from 12 to 30 mg doses are shown in
Figure S1 in the supplementary material. The maximum simulated
ivermectin concentrations in plasma and lung were 288 and
772 ng/mL respectively at 5.1 hwhich is similar to published time to
maximum concentration values.17Discussion
Interest in the utilization of ivermectin against SARS-CoV-2 as a
potential treatment for COVID-19 increased after the demonstra-
tion of its in vitro activity.11 To understand the predicted exposure of
ivermectin in the lungs, where SARS-CoV-2 causes infection and
diffuse alveolar damage, we developed an mPBPK model utilizing
the cattle-informed Kp,lung/F parameter as well as the geometric
mean plasma profile based on a published population PK model.
The population PK model was selected because it provided a
conservative estimate of the mean plasma concentration profile
that produced parameters in agreement with a published meta-
analysis on ivermectin PK.13,17 In our opinion, these plasma data
provide a conservative estimate of simulated lung exposure as the
mPBPKmodel was developed based off the geometric mean plasma
concentration profile. Our simulated peak lung concentration of
772 ng/mL following a single oral 120 mg dose is well below the
reported in vitro IC50 of 1750 ng/mL as seen by other groups.11,18,19
The mPBPK model allows the simulation of different formulations
(e.g., an ethanol-containing solution shown to have approximately
twice the systemic availability of ivermectin tablets) as well as theeffect of high fat meals to increase lung exposure to ivermectin.17
Reformulation of ivermectin to an inhaled therapy may increase
drug exposure in the lungs while minimizing the potential toxic-
ities associatedwith high plasma concentrations that have not been
established as safe.
Ivermectin is a compelling candidate for consideration as part of
a combination regimen by making the host cell environment un-
favorable for SARS-CoV-2 assembly and replication after IMPa/b1
heterodimer dissociation and inhibition.8e10 Ivermectin is also
lipophilic with a pKa > 8, which has been shown to be beneficial for
Fig. 2. Observations and predictions of the mPBPK model illustrated in Fig. 1. Simulated plasma concentrations from a historical Phase I study of patients receiving a 0.2 mg/kg dose
of ivermectin are represented by red circles, and the model prediction is represented by the blue line.
Fig. 3. Simulations following oral administration of a single 120 mg ivermectin dose. (A) Median ivermectin concentration in the lung (blue) and 95% CI from simulation of 1000
subjects. The dashed line represents the published in vitro ivermectin IC50 of 1750 ng/mL against SARS-CoV-2. (B) Median ivermectin concentration in the plasma (red) and 95% CI
from simulation of 1000 subjects.
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ivermectin in combination with other agents of differing antiviral
mechanisms of action could be efficacious and/or reduce the iver-
mectin exposure necessary to eradicate SARS-CoV-2 through syn-
ergistic effects.
Although our model development and approach is unique
compared to current literature, our results and conclusions are in
agreement with previous analysis in regards to iveremctin's po-
tential as a COVID-19 therapeutic agent.18,19 Our efforts are different
in that we have provided a framework for mPBPK model devel-
opment that can be utilized for any future compound thought to be
a potential treatment option for COVID-19. Also, by providing the
differential equations, future investigators will not be limited by
the modeling software/tool available to them and will be able to
implement this mPBPK model structure. Our mPBPK model can be
applied to the future directions stated by previous investigators
through enabling optimization of either systemic or inhalational
doses.
Themain limitations of our approach are the inability to validate
our simulated human lung exposure with any published values as
well as not being able to simulate drug accumulation in tissue after
multiple dosing. Ivermectin is highly protein bound (~93%), and the
proposed simulation represents the total ivermectin concentra-
tion.17,21 Total ivermectin concentrations were simulated because
protein binding in the lung has not been assessed, but it is likely the
free drug concentration is significantly lower than the 772 ng/mL
peak lung concentration simulatedwhich reinforces the need for an
inhalational dose. Ruminants such as cattle have similarly high
plasma binding compared to humans (96e99%), and total iver-
mectin concentration was assessed by Lifschitz and colleagues.12,22
Also, because of the similarity in plasma binding of ivermectin
between species, the Kp,lung/F was considered species-independent
due to the assumed similar impact plasma binding would have on
distribution which is an assumption commonly made in physio-
logically based pharmacokinetic modeling.23 The low parameter
estimate of 0.08 for the fraction of cardiac output that perfuses the
rest of the body (Fraction) indicates the disposition of ivermectin is
perfusion rate-limited. This is a common generic assumption for
PBPK models and is also typical of small lipophilic molecules such
as ivermectin (logP ¼ 5.83).24
To conclude, we successfully developed an mPBPK model to
simulate ivermectin lung exposure in humans after oral dosing.
Simulated concentration profiles of single-dose ivermectin
administered orally at doses proven to be safe in clinical studies did
not achieve lung concentrations above the published in vitro IC50
concentration for SARS-CoV-2. Clinical trials of ivermectin refor-
mulated for inhalational delivery or in vitro studies assessing syn-
ergy of ivermectin in combination with antiviral agents of differing
mechanisms of action are needed to understand ivermectin's value
in the treatment of COVID-19. This approach for model develop-
ment can be used for current and future COVID-19 therapeutic
agents of interest as the repurposing of approved compounds
continues.Appendix A. Supplementary Data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.xphs.2020.08.024.
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